Page 3 - Attack Point News Today : Breaking News, Live Updates & Top Stories | Vimarsana

On tiktok close to a ukrainian city. still plenty of troops along the belarusian and russian borders with ukraine. even if a few battalions have moved from crimea, that is unlikely to have been the attack point anyway. unlikely to have been the attack point anyway-— point anyway. you are a disinformation - point anyway. you are a disinformation expert, i point anyway. you are a i disinformation expert, and point anyway. you are a - disinformation expert, and over point anyway. you are a _ disinformation expert, and over this crisis, there's been lots of conflicting information. and while the...

Tank, to find out if there has been any evidence of withdrawal of russian troops. looking at the open source intelligence that's available on the internet, as well as ordinary russians who are posting lots of videos on platforms like tiktok, we have seen no evidence of withdrawal either. in fact, there is satellite imagery showing that russian troops have built a bridge across the pripyat river, which is about six to four km away from the ukrainian border with belarus. and this is deep in the chernobyl nuclear exclusion zone, where people shouldn't be, so this is a very staggering sign, as is ...

Ukrainians consider themselves vanquished. general keith kellogg. thanks for joining us. what do you think, that taking a city and occupying a city are two different things. >> you are spot-on. putin put himself in a real box. one, he has a lot of hubris. he thought he could do this on the cheek. cyber is an example. he should have shut everything down. he didn't. and what do you have? you have president zelensky talking to the ukrainians and the russians as well. he didn't attack his main attack point which is decapitate the government. go after zelensky. he didn't do it.

Mit Tafasitamab ist ein neuer Antikörper zur Behandlung einer bestimmten Form des Non-Hodgkin-Lymphoms auf den deutschen Markt gekommen.

- Progressionsfreies Überleben (PFS) unter Derazantinib-Monotherapie auf acht Monate verlängert Basel, 17. September 2021 Basilea Pharmaceutica AG (SIX: BSLN) gab heute die Veröffentlichung